Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dalpiciclib and Letrozole in HR+/HER2- Breast Cancer
NCT05512416Phase 2Unknown
- Sponsor
- The Affiliated Hospital of Qingdao University
- Start
- Aug 2022
- Primary completion
- Aug 2023
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of dalpiciclib in Hormone-Receptor-Positive Breast Cancer, sponsored by The Affiliated Hospital of Qingdao University. Primary endpoint: Complete cell-cycle arrest at C1D15 at 15 days. Status: unknown.
02
Drugs
dalpiciclib
03
Conditions
Hormone-Receptor-Positive Breast Cancer
Beyond the preview
Go deeper on NCT05512416.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05512416.